The product’s main indication is treatment of severe infections caused by aerobic and anaerobic gram-positive organisms, including infections accompanied by bacteremia:

  • community-acquired pneumonia;
  • nosocomial pneumonia;
  • skin and soft tissue infections;
  • enterococcal infections of different localization, including vancomycin-resistant strains.


  • active against all clinically significant gram-positive bacteria, including multidrug-resistant (vancomycin- and methicillin-resistant) strains;
  • minimum levels of pathogen resistance;
  • there is no need to adjust dosage for patients with hepatic and renal failure;
  • proven clinical and microbiological efficacy in methicillin- and vancomycin-resistant infections.
How supplied
300 ml
Sales markets

Georgia, Uzbekistan, Philippines, Ukraine.